The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major: a double‐blind randomized controlled clinical trial
| Title: | The effects of curcumin on hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major: a double‐blind randomized controlled clinical trial |
|---|---|
| Authors: | Aziz Eghbali, Shima Nourigheimasi, Ali Ghasemi, Roghayeh Rahimi Afzal, Neda Ashayeri, Aygin Eghbali, Shokoufeh Khanzadeh, Kazem Ghaffari |
| Source: | Frontiers in Pharmacology, Vol 14 (2023) |
| Publisher Information: | Frontiers Media S.A., 2023. |
| Publication Year: | 2023 |
| Collection: | LCC:Therapeutics. Pharmacology |
| Subject Terms: | curcumin, liver enzymes, β-thalassemia major, T2∗MRI, aspartate transaminase, randomized clinical trial, Therapeutics. Pharmacology, RM1-950 |
| More Details: | Background: Curcumin present in turmeric has been considered due to its cancer-preventive features, antioxidant and anti-inflammatory properties. This double-blind, randomized, controlled clinical trial with a reasonable sample size and longer intervention period was conducted to investigate how oral curcumin affected cardiac and hepatic T2*MRI and liver enzymes in patients with β‐thalassemia major.Method: This clinical trial study was conducted on 171 patients over 5 years old. The subjects were randomly divided into a curcumin-treatment group and a placebo group to receive either curcumin capsules twice daily or placebo for 6 months. Patients were examined once a month for 6 months to receive capsules and measure the levels of alanine aminotransferase (ALT), aspartate transferase (AST), alkaline phosphatase (ALP), direct and total bilirubin, ferritin and cardiac and hepatic T2*MRI.Result: There was a significant decrease in levels of AST, ALT, ALP, and bilirubin (direct and total) in the curcumin group compared with the placebo group by the end of the study (p < 0.05). The levels of serum ferritin remained unchanged in both groups at the end of the follow‐up period (p > 0.05). No significant differences were observed between the curcumin and placebo groups at baseline values or at the end of the study of cardiac and hepatic T2*MRI and serum magnesium.Conclusion: Administration of curcumin has some beneficial effects on liver function by reducing liver enzymes in patients with beta-thalassemia major. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1663-9812 19005709 |
| Relation: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1284326/full; https://doaj.org/toc/1663-9812 |
| DOI: | 10.3389/fphar.2023.1284326 |
| Access URL: | https://doaj.org/article/745ba798f5b44289ba19005709d0b83b |
| Accession Number: | edsdoj.745ba798f5b44289ba19005709d0b83b |
| Database: | Directory of Open Access Journals |
| ISSN: | 16639812 19005709 |
|---|---|
| DOI: | 10.3389/fphar.2023.1284326 |
| Published in: | Frontiers in Pharmacology |
| Language: | English |